Difference between peginterferon alfa 2a and 2b

Common Questions and Answers about Difference between peginterferon alfa 2a and 2b

pegasys

4920683 tn?1370195521 Two kinds of pegylated interferons are available -- peginterferon alfa-2a (also called alfa-2a) and peginterferon alfa-2b (also called alfa-2b). The main difference between these two pegylated interferons is in the dosing. Alfa-2a is used as a fixed weekly dose. Alfa-2b is used as a weekly dose based on the weight of the patient. There are other differences between the two drugs, but they are mostly technical and are used by the prescribing physician.
476246 tn?1418870914 Most patients who did not tolerate peginterferon alfa-2b/ribavirin due to AEs and who completed the full 36-week course of peginterferon alfa-2a/ribavirin treatment achieved SVR.
Avatar m tn Taken together, since the publication of the pivotal phase 3 trials for peginterferon alfa-2a and alfa-2b in combination with ribavirin, it took another 8 years to characterize the pharmacodynamic differences between the 2 drugs in detail," Zeuzem wrote.
4384361 tn?1399998230 NE Journal of Medicine: Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection http://www.nejm.org/doi/full/10.1056/NEJMoa0808010 (the rates of sustained virologic response and tolerability did not differ significantly) Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials http://www.ncbi.nlm.nih.gov/pubmed/20187106 http://www.medhelp.
1375580 tn?1278739099 I think alfa-2a and alfa-2b are comparable for results as far as SVR goes. I also think that alfa-2a is sometimes better tolerated and has become the defacto standard. Maybe someone who has treated with alfa-2b can offer more information. I treated with alfa-2a and had the usual side effects, maybe a little worse than many since I had a long TX period, but it beats progression of liver disease by a long shot.
148588 tn?1465778809 24 weeks of telaprevir plus peginterferon alfa-2a and no ribavirin (T24/P24); or 48 weeks of peginterferon alfa-2a/ribavirin (the control arm) (PR48).
541844 tn?1244309824 The only time a study shows that much of a difference in response rates between the two products is when you take patient compliance into account - in other words, Pegasys seems to have easier side effects, so easier to stay on full dose. If everything else were equal and 2b and 2a were both bonded to a branched PEG molecule, I'm guessing 2b might actually come out a little better SVR, but that's just a guess. Tell your doctor you're a 'Pegasyssy' and want the easy stuff.
Avatar n tn I've taken both 2a & 2b. For me, 2a had less side effects. I've been told that 2a has a smaller peg than 2b and that's why it has less side effects. I'm not a chemist so I can't confirm that information. Just know that 2a was better for me.
Avatar n tn I want to know if there are any clinical comparative studies on the efficacy and potency between Peg IFN Alfa 2a (pegasys) and peg IFN Alfa 2b (pegintron). I am about to begin the treatment to get rid of the virus and i am doing more readings and research into this one. I weigh 103 kg 30 yrs old. got a 10million viral load. your help is highly appreciated. Thank you.
Avatar m tn Sustained ALT 6 normalization at 24 weeks off treatment was greater after peginterferon alfa-2a compared to lamivudine and after combined therapy of peginterferon alfa-2a with lamivudine compared to lamivudine alone. Histological improvement off treatment in necroinflammatory scores was reported in only one RCT95 after peginterferon alfa-2a compared to lamivudine in HBeAg-negative patients. Combined virologic and biochemical outcomes.
Avatar m tn Selection of Weight-Based Peginterferon alfa-2b or Fixed-Dose Peginterferon alfa-2a Large clinical trials suggest that in genotype 1 HCV–infected patients treated with peginterferon alfa-2a or alfa-2b plus ribavirin (at variable dosing), SVR rates range between 42% and 46%. However, differences in study design, treatment regimens, and patient populations preclude comparison of the data across these trials.
Avatar m tn Ocular side effects associated with oral ribavirin in combination with peginterferon alfa-2a, peginterferon alfa-2b, or interferon alfa-2b have included blurred vision (up to 6%). Corneal ulcer has been reported in less than 1% of patients treated with peginterferon alfa-2a alone or in combination with ribavirin tablets. Conjunctivitis (up to 5%) has been reported with ribavirin capsules/oral solution in combination with peginterferon alfa-2b or interferon alfa-2b.
Avatar f tn MRK), known as MSD outside of the United States and Canada, reported that final results from a Phase III study of VICTRELIS™ (boceprevir), its investigational oral hepatitis C protease inhibitor, added to peginterferon alfa-2a (Pegasys®) and ribavirin therapy demonstrated significantly higher sustained virologic response (SVR)1 rates in adult patients who failed previous treatment for chronic hepatitis C virus (HCV) genotype 1 compared to a control group receiving peginterferon alfa-2a and riba
Avatar m tn Among patients who had portal hypertension (42.3% and 48.0% of patients in the peginterferon alfa-2b and colchicine groups, respectively), peginterferon alfa-2b therapy resulted in significantly improved event-free survival in both the ITT and on-drug analyses (Wilcoxon p = 0.041 and 0.028, respectively). Further, variceal bleeding, a specific complication of portal hypertension, was almost abolished with peginterferon alfa-2b in both the ITT (10 vs. 1 patients) and the on-drug (10 vs.
Avatar m tn 1 basis, in combination with ribavirin. The overall results identified no significant difference in SVR rate between patients treated with standard-duration vs variable-duration therapy (45.1% vs 48.8%, respectively; P = .37). Although still not significant, the SVR rate for patients who achieved undetectable HCV RNA at Week 12 was 38.1% with standard therapy compared with 63.5% with variable therapy—a difference that showed a trend toward significance (P = .068).
511080 tn?1211208992 The medications currently approved by the US Food and Drug Administration (FDA) for the initial treatment of chronic hepatitis B include interferon alfa-2b, peginterferon alfa-2a, and the oral nucleoside/nucleotide analogs lamivudine, adefovir dipivoxil, entecavir, and telbivudine, with tenofovir under FDA review for likely approval in 2008. Each of these drugs has a number of advantages and disadvantages.
Avatar m tn Most patients who did not tolerate peginterferon alfa-2b/ribavirin due to AEs and who completed the full 36-week course of peginterferon alfa-2a/ribavirin treatment achieved SVR. PMID: 18081737 [PubMed - as supplied by publisher] peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J Viral Hepat. 2007 Oct;14(10):721-9 Di Bisceglie AM, Ghalib RH, Hamzeh FM, Rustgi VK.
694630 tn?1227710675 today announced that Albuferon(R) (albinterferon alfa-2b) met its primary endpoint of non-inferiority to peginterferon alfa-2a (Pegasys) in ACHIEVE 2/3, a Phase 3 clinical trial of Albuferon in combination with ribavirin in treatment-naive patients with genotypes 2 and 3 chronic hepatitis C (p=0.0086). Albinterferon alfa-2b is being developed by HGS and Novartis under an exclusive worldwide co-development and commercialization agreement entered into in June 2006.
Avatar n tn Pegasys is a brand name for Peginterferon alfa-2a or Pegylated interferon alfa-2a which is an antiviral drug made by La Roche. It is given by injection. It is used in combination with another medication called Ribavirin (a pill), and a third medication, either Victrellis or Incivek, which are both pills, to treat Hepatitis C. Let us know if you have further questions.
Avatar m tn [24] Therefore, it is the recommendation of this author to reduce ribavirin stepwise by 200 mg every 2-4 weeks until adverse events either resolve or are tolerable. Peginterferon alfa-2a can be reduced from 180 to 135 µg/week and peginterferon alfa-2b from 1.5 to 1.0 µg/kg/week. Neither peginterferon alfa nor ribavirin dosing should be interrupted unless the adverse event is particularly severe and there is a concern for patient safety.
1476285 tn?1287337784 A relationship between RBV dose and response to therapy with both IFN alpha-2a and alpha-2b has been established in genotype 1 patients, who benefit from doses that exceed 800 mg/day (5, 14). When RBV is combined with PEG-IFN alpha-2a, relatively small reductions to 800 mg/day lead to significantly lower rates of SVR (5).
168246 tn?1212063254 Peginterferon alfa-2a can be reduced from 180 to 135 µg/week and peginterferon alfa-2b from 1.5 to 1.0 µg/kg/week. Neither peginterferon alfa nor ribavirin dosing should be interrupted unless the adverse event is particularly severe and there is a concern for patient safety. Whenever the doses of peginterferon alfa and ribavirin are modified or temporarily interrupted, HCV RNA testing should be performed again to ensure that breakthrough has not occurred." 15.
2030686 tn?1351688548 Ocular side effects associated with oral ribavirin in combination with peginterferon alfa-2a, peginterferon alfa-2b, or interferon alfa-2b have included blurred vision (up to 6%). Corneal ulcer has been reported in less than 1% of patients treated with peginterferon alfa-2a alone or in combination with ribavirin tablets. Conjunctivitis (up to 5%) has been reported with ribavirin capsules/oral solution in combination with peginterferon alfa-2b or interferon alfa-2b.
Avatar m tn what is the difference (related to HBV ) between Interferon alfa-2a and Interferon alfa-2b ?
Avatar f tn These meds are through Roche. Pegasys (peginterferon alfa-2a) and Copegus (ribavirin) which is Roche and Pegintron (peginterferon alfa-2b) and Rebetol (ribavirin) which is Schering-Plough. Both are considered the current SOC.
Avatar f tn The T12(DS)/PR48 group had a lead-in (delayed start of INCIVEK) with placebo and Peg-IFN-alfa-2a/RBV for 4 weeks, followed by INCIVEK and Peg-IFN-alfa-2a/RBV for 12 weeks, followed by Peg-IFN-alfa-2a/RBV for 32 weeks. The Pbo/PR48 group received placebo and Peg-IFN-alfa-2a/RBV for 16 weeks, followed by Peg-IFN-alfa-2a/RBV for 32 weeks.
Avatar f tn This trial definitively demonstrated the lack of utility of maintenance peginterferon alfa-2a, as there were no significant differences in the rates of primary outcomes between the peginterferon alfa-2a maintenance and control groups (34.1% vs 33.8%, respectively).